BACKGROUND: The intestinal microbiome in early infancy affects immunologic development and thus may affect vaccine memory, though few prospective studies have examined such associations. We examined the association of Bifidobacterium levels in early infancy with memory responses to early vaccination measured at 2 years of age.
WHAT'S KNOWN ON THIS SUBJECT: The composition of the gut microbiome affects many aspects of immune function and is known to affect response to vaccination over the short-term.
WHAT THIS STUDY ADDS:
We demonstrate that a high abundance of Bifidobacterium in early infancy when infants receive several vaccines is associated with better vaccine memory, as indicated by higher responses to Bacillus Calmette-Guérin, polio, and tetanus vaccines measured at 2 years of age. Vaccines are estimated to prevent 3 million childhood deaths annually. 1 Vaccine memory involves the development of antibody-producing plasma cells and effector T cells, whereas maintenance of memory involves the persistence of memory B and T cells. 2, 3 Vaccine-elicited T-cell and antibody responses as well as protective efficacy vary substantially among individuals for reasons that are not completely understood. [4] [5] [6] Recent evidence suggests that part of this variability is due to interactions between the intestinal microbiome and the developing infant immune system. 7 The importance of intestinal microbes for the development of the mammalian immune system is well documented. The absence of bacteria in germ-free mice affects both local [8] [9] [10] [11] and systemic lymphoid compartments, 9, 10 whereas colonization with specific commensal bacteria [12] [13] [14] affects both innate and adaptive immunity. 15 Disruption of normal development of the intestinal microbiome may have adverse immunologic consequences. Quantitative or qualitative "deficiencies" in microbial exposure during infancy increases subsequent risk of atopic diseases including asthma, 16 whereas the early administration of probiotic bacteria is associated with a decreased risk of atopic eczema. 17 Researchers have examined in only a few human studies the relationship of naturally occurring gut bacteria with immune function, although members of the Bifidobacterium genus have been associated with higher levels of immunoglobulin A (IgA)-secreting plasma cells, 18 memory B-cells, 19 and salivary IgA, 20 suggesting a beneficial relationship for the infant.
Establishment of the intestinal microbiome begins early in infancy and follows a typical pattern. 21 Facultative anaerobic bacteria such as Staphylococcus, Streptococcus, Lactobacillus, and Escherichia initially colonize the colon, followed by strict anaerobes that come to predominate during the first few months of life. In breastfed infants Bifidobacterium longum subspecies infantis often dominates the microbiome because it is specifically adapted to both use human milk oligosaccharides as a carbon source and to restrict human milk oligosaccharides availability to other bacteria. 22 Bacteroides and clostridia are also important commensal anaerobes in the infant gut. 21 The abundance of Bifidobacterium species (relative to total bacteria) can exceed 60% in breastfed infants in countries like Bangladesh where breastfeeding is widespread. 23, 24 The abundance of B longum subspecies infantis is lower in the United States and other Western countries and appears to have decreased over recent decades, 25 concurrent with the rise in autoimmune and allergic diseases.
In the current study, we evaluate the hypothesis that greater exposure to Bifidobacterium (and to B longum subspecies infantis in particular) early in infancy when vaccines are administered will result in better memory responses to these vaccines. We previously reported that a high abundance of Bifidobacterium, and of B longum subspecies infantis, at 15 weeks was associated with higher vaccine responses measured at the same time. 24 In that study, we examined a subset (n = 48) of infants in a birth cohort of 306 infants. In the current study, we measure the vaccine responses of all available infants at 2 years of age to test the hypothesis that Bifidobacterium abundance at 6, 11, and 15 weeks of age is predictive of vaccine responses measured at 2 years. We examine responses to 4 vaccines: tetanus toxoid (TT) and hepatitis B virus (HBV) given at 6, 10, and 14 weeks; Bacillus Calmette-Guérin (BCG), given within 48 hours of birth; and oral polio virus (OPV), given within 48 hours of birth and at 6, 10, and 14 weeks. We also examine vaccine responses measured at 6 and 15 weeks to increase the sample size of our previous report. 24
METHODS

Study Design
In this study, we re-recruited all available participants from a randomized controlled trial of vitamin A supplementation at birth (www.clinicaltrials.gov identifier: NCT01583972) and measured additional vaccine responses at 2 years in the same infants (NCT02027610) (Supplemental Table 4 ). The study was approved by the Research Review Committee and the Ethical Review Committee of the International Centre for Diarrhoeal Disease Research, Bangladesh. The inclusion-exclusion criteria, study design, laboratory methodology, clinical procedures, and baseline characteristics of the participants have been described. 26
Vaccine Responses Assay
Vaccine-specific CD4 T-cell stimulation index (SI), antibody in lymphocyte supernatant (ALS) responses and the purified protein derivative delayed-type hypersensitivity (DTH) skin test response were measured as described in our earlier report. 26, 27 All of the vaccines are T-cell-dependent in that a robust T-cell response is needed for protection. Thus, we view the SI as a proxy for the magnitude of memory response (ie, the number of memory T cells). Stool extracts were prepared as described 28 to measure poliospecific IgA by using an in-house enzyme-linked immunosorbent assay (ELISA) described in the Supplemental Information. Antibody avidity index (AI) of plasma polio specific immunoglobulin G (IgG) and IgA, HBV-specific IgG, and TT-specific IgG at 2 years was determined by ELISA by using a chaotropic agent as described in the Supplemental Information.
Microbiota Assay
Overall stool microbial composition was determined by using 16s V4 sequencing method 24 modified as described in the Supplemental Information. Abundance at the genus level refers to the abundance of Bifidobacterium genomes relative to all bacterial genomes. A terminal restriction-fragment lengthpolymorphism assay was used to identify bifidobacteria at the species level by comparing fragment lengths to published data. 29 Details are provided in the Supplemental Information and previous publications. 24, 30 
Statistical Analysis
The associations between bifidobacteria and vaccine-specific immune responses were determined by multiple regression analysis by using the mean Bifidobacterium abundance during early infancy (6, 11 , and 15 weeks) and at 6 weeks only, and the abundance of Bifidobacterium species and subspecies measured at 6 weeks, as independent variables. The analysis was adjusted for possible covariates, including sex, vitamin A or placebo treatment, birth weight (above or below median), and type of delivery (cesarean delivery or vaginal). Breastfeeding status (exclusive or nonexclusive) during early infancy affects Bifidobacterium abundance and could independently affect vaccine responses and was thus evaluated as a covariate in our model. It was statistically significant in only 2 cases and was thus not included in the final model. However, examination of stool IgA responses to OPV at 2 years could be affected if breastmilk contained OPV-specific IgA. Thus, we included breastfeeding status (yes or no) in the regression analysis at 2 years. A P value of ,.05 was considered statistically significant for all analyses. Data are presented as means 6 SD unless otherwise indicated. Statistical analysis was performed by using R version 3.4.2. 31 
RESULTS
Characteristics of Study Infants
Microbiota data were available from 291 infants at 6, 11, and 15 weeks, and from 249 of these same infants at 2 years. Half of the participants were boys, and half received a high-dose vitamin A supplement within 48 hours of birth as prescribed by the parent study ( Table 1 ). The majority of infants were born by elective cesarean delivery, as is typical for hospital deliveries in Bangladesh. 26 At 6 weeks, all infants were exclusively or predominantly breastfed, and at 2 years, 55% received supplemental breastfeeding. Infants were healthy on the days of sample collection but a small percentage had elevated C-reactive protein (CRP), indicating an ongoing acute phase response (Table 1) .
Bifidobacteria Were the Most Abundant Taxa
All infants had detectable Bifidobacterium at 6 weeks and the mean abundance for 6, 11, and 15 weeks was 0.637 with a range 0.020 to 0.921 (Supplemental Table 5 ). Species and subspecies of Bifidobacterium were measured at 6 weeks, and B longum was by far the most abundant species, at 0.581, followed distantly by Bifidobacterium breve and Bifidobacterium bifidum at 0.032 and 0.014, respectively. We further analyzed the 2 subspecies of B longum and found that B longum subspecies infantis (abundance, 0.568) was predominant, being ∼10fold more abundant than B longum subspecies longum (abundance, 0.058), as expected.
Bifidobacteria Abundance Was Positively Associated With the CD4 T-Cell Response to the BCG Vaccine
The BCG vaccine was given once within 48 hours of birth. Although intestinal bacterial communities were not established at that time, we hypothesized that such communities established between 6 and 15 weeks would affect maintenance of the BCG memory response. We tested this hypothesis using multivariate regression analysis to adjust for other factors that could also affect vaccine responses and found that mean Bifidobacterium abundance in early infancy (measured at 6, 11, and 15 weeks; Table 2 ) and Bifidobacterium abundance measured at 6 weeks only (the closest time to vaccination; Supplemental Table 6 ) were both positively associated with the CD4 memory T-cell responses (measured as the SI) at 15 weeks and 2 years but not at 6 weeks (Fig 1) . For infants with high mean Bifidobacterium abundance (90th percentile of study population, abundance = 0.814), the estimated SI at 15 weeks was 85% higher than for infants with low Bifidobacterium abundance (10th percentile abundance = 0.396), whereas the difference at 2 years was 64% ( Table 3 ). No significant associations were seen between Bifidobacterium abundance and the DTH skin-test response for BCG ( Fig 1) .
In addition to Bifidobacterium abundance at the genus level, Bifidobacterium species and subspecies were measured at 6 weeks, and we examined these associations as well, primarily to determine if the predominant species (B longum) and subspecies (B longum subspecies infantis) were also associated with these vaccine responses. In brief, we found that both B longum (Supplemental Table 7 ) and B longum subspecies infantis (Supplemental Table 8 ) were significantly associated with the SI response at 15 weeks but not 2 years (Fig 1) . We also examined associations for the less abundant Bifidobacterium subspecies (B longum subspecies longum Supplemental  Table 9 ) and 2 minor Bifidobacterium species (B breve and B bifidum; Supplemental Tables 10 and 11 , respectively), and no significant associations were seen (Fig 1) . Association between infant' s Bifibacterium abundance and 6 wk vaccine response was analyzed by using genus Bifibacterium abundance at 6 wk of age. Association between infant' s Bifibacterium and 15 wk and 2 y analysis were done on mean genus Bifibacterium abundance at 6 wk, 11 wk, and 15 wk of age. The regression models were adjusted with sex, treatment group, birth weight, and type of delivery. Stool antibody models were additionally adjusted for breastfeed status at 2 y of age. a Vaccine response was significantly different between boys and girls. b Vaccine response was significantly different between treatment groups. c Vaccine response was significantly different between normal and cesarean delivery. d Vaccine response was significantly different between below and above birth weight median.
significantly associated with the SI for SEB at 15 weeks (Fig 1) .
Bifidobacteria Abundance Was Positively Associated With Responses to TT and HBV Vaccines
TT and HBV vaccines were administrated at 6, 10, and 14 weeks, within the period when bifidobacteria abundance was assessed, and we thus hypothesized that bifidobacterial abundance would be positively associated with the SI and IgG responses to both vaccines when they were measured at 15 weeks and 2 years. In partial confirmation of this hypothesis, Bifidobacterium, B longum, and B longum subspecies infantis abundance were all positively associated with the SI responses to both TT and HBV when they were measured at 15 weeks and with the TT SI response at 2 years, but they were not positively associated with the HBV response at 2 years (Fig 2) . At 15 weeks, the predicted SI values for infants with high Bifidobacterium abundance were 76% and 45% higher than for those with low abundance for TT and HBV responses, respectively, whereas the corresponding difference at 2 years for TT was 57% ( Table 3) .
Bifidobacterium abundance at the genus level was positively associated with the IgG responses to the TT vaccine when measured both at 15 weeks and at 2 years, whereas a similar association was seen at 15 weeks for B longum abundance (Fig 2) . The predicted TT-specific IgG concentration at 2 years was 42% higher in infants with high versus low Bifidobacterium abundance ( Table 3 ). Bifidobacterium at the genus level was not associated with the HBV IgG response at either 15 weeks or 2 years, although HBV-specific IgG at 15 weeks and plasma IgG maturation index at 2 years were negatively associated with B breve and B longum subspecies longum, respectively (Fig 2) . All infants had protective IgG titres for both TT ($0.1 IU/mL) and HBV ($10 mIU/mL) at 2 years.
The generally positive associations of Bifidobacterium, B longum, and B longum subspecies infantis abundance with TT vaccine responses found in regression analysis can be seen graphically (without adjustment for covariates) in scatterplots of the raw data at 15 weeks (Supplemental Fig 5) and 2 years (Fig 3) .
Bifidobacteria Abundance Was Positively Associated With IgG and IgA Responses to OPV Vaccine
OPV vaccine was administered within 48 hours of birth and again at 6, 10, and 14 weeks. We hypothesized that bifidobacterial abundance would be positively associated with OPV vaccine responses, which included the total IgG response at 15 weeks and strain-specific responses (3 strains are found in the OPV vaccine) at 2 years (plasma IgG and IgA, and stool IgA). In partial agreement with our hypothesis, the abundance of Bifidobacterium was positively associated with polio-specific stool IgA at 2 years (Fig 4) , with the predicted response being 107% higher in infants with high versus low Bifidobacterium abundance (Table 3) . This association can also be seen graphically with unadjusted data (Fig 3) . Plasma IgA at 2 years also revealed some positive bifidobacterial associations (Fig 4) , including positive associations of both Bifidobacterium and of B longum with the poliovirus strain 3 IgA response, whereas a negative association was seen between B breve and the strain 1 response (Fig 4) . B bifidum abundance was positively associated with plasma IgG concentration at 2 years, whereas mean Bifidobacterium abundance was positively associated with the IgG AI (Fig 4) . Two negative associations were also seen: B longum subspecies longum with 15 weeks IgG and B breve with 2 years plasma poliospecific IgA.
DISCUSSION
Higher bifidobacteria abundance in early infancy is associated with better memory responses to vaccines given at this time, as judged by the magnitude of the vaccine responses measured at 2 years. Mean Bifidobacterium abundance measured at 6, 11, and 15 weeks, and Bifidobacterium abundance measured at 6 weeks only, performed similarly in predicting later vaccine responses. These findings are novel and support current thinking about how gut microbiota may shape development of the infant immune system. 7, 32 For example, higher Th1 responses are associated with bifidobacterial abundance 33 and a microbial state with low Bifidobacterium, Akkermansia, and Faecalibacterium in early infancy is associated with atopic CD4 T-cell responses at 2 years and asthma development at 4 years. 34 In addition, vaccinia virus-specific interferon-g production by CD8 T cells, 35 and human serum albumin-specific and cholera toxin-specific interferon-g and interleukin-5 production by splenocytes 36 postvaccination are both influenced by gut microbial composition. These studies also suggest a cause-effect relationship between gut microbiota and vaccine responses. Our results suggest a general effect of bifidobacteria on T-cell proliferation or survival, as indicated by the association of bifidobacteria levels with both vaccine-specific and SEB-stimulated T-cell proliferation, whereas the lack of an association with SEB-stimulated proliferation at 2 years suggests an independent association with maintenance of vaccine memory.
Gut bacteria affect development of T cells, particularly Treg and Th17 cells. 12, 37 Bifidobacterial effects on T-cells could be direct or might involve effects on dendritic cells which then affect T cells, and these effects may be mediated by production of small-molecule bacterial metabolites including short chain fatty acids. [38] [39] [40] Bacterial macromolecules also affect immunity. Both lipopolysaccharide 41, 42 and flagellin 43 act as vaccine adjuvants, presumably via toll-like receptor 4 and toll-like receptor 5, respectively, suggesting that commensal bacteria may act as natural vaccine adjuvants. 44 Indirect mechanisms may also be relevant. For example, Bifidobacterium protects against enteropathogenic infection 45 and reduces the relative abundance of Enterobacteriaceae 46 and thus may improve vaccine responses by reducing the risk of symptomatic infections or subclinical dysbiosis.
Many studies report associations of gut microbiota with vaccine-specific antibody responses. 7 In the current study, we report positive associations of early life bifidobacteria with TTspecific IgG responses both in early infancy and at 2 years, and with poliospecific IgA at 2 years, suggesting a sustained effect on vaccine memory. A study examining rotavirus vaccine response among infants in Ghana 47 found no associations with Actinobacteria (the phylum containing bifidobacteria), but reported that serum IgA was negatively associated with Bacteroidetes and positively associated with Streptococcus bovis. The same group performed a similar study in Pakistani infants and found no association with Bifidobacterium. 48 The infants in the current study did not receive rotavirus vaccine. A previous study found that abundance of B breve and B longum 49 were both positively correlated with polio-specific stool IgA measured shortly after vaccination. In the current study, we also report a nonsignificant (P = .088) positive association between Bifidobacterium and HBV-specific IgG at 2 years. A previous human study 50 using B longum and Lactobacillus rhamnosus supplementation in infants also showed a trend toward an increased HBV-specific IgG response. In another study, the abundance of Bacteroides ovatus and Streptococcus geniculate in nasal microbiota were positively and negatively associated with IgA responses, respectively, to intranasal influenza vaccination. 51 We also report that the B breve was negatively associated with polio-specific plasma IgA, a finding that is consistent with another study 52 revealing that B breve supplementation lowers the serum IgA response to cholera vaccination. In our study, we also found a negative association between B longum subspecies longum and polio-specific ALS IgG at 15 weeks. Such results emphasize the need to identify the mechanisms by which specific bifidobacteria affect immunity.
Strengths of our study include the examination of short-and long-term memory responses, the relatively large sample size, the use of specific assays for bifidobacteria at the species and subspecies level, the use of multiple vaccines and of multiple vaccine end points, and the prospective study design. Our study is limited in that it is observational, thus we cannot infer causality from the associations described here, and participants were all breastfed, limiting the diversity in intestinal microbiota seen in study infants. Additionally, although BCG and the OPV are not used in developed countries, the similarity in associations seen in this study to that seen in a small study of inactivated polio virus, 49 as well as the associations to the more widely administered HBV and TT vaccines, suggest that these results are relevant for many populations of infants around the world. 
CONCLUSIONS
Colonization with Bifidobacterium at the time of vaccination is associated with sustainable systemic and mucosal vaccine-specific memory T-cell and antibody responses. Developing strategies to enhance immunologic memory is a high priority for vaccine research. 53 A recent intervention trial demonstrated that administration of probiotic B longum subspecies infantis to healthy infants between 7 and 28 days significantly increased the abundance of this organism through at least 60 days, 46 demonstrating prolonged colonization with this organism in breastfed infants. An adequately powered randomized controlled trial of a similar strategy to increase early colonization with B longum subspecies infantis to enhance responses to early vaccination is indicated by our findings.
FIGURE 4
Heat map showing associations (and statistical significance) between early life bifidobacteria abundance and OPV vaccine responses measured at 15 weeks and 2 years of age determined with multiple regression analyses as described in Methods. Responses include the CD4 T-cell SI, the ALS assay for IgG at 15 weeks, plasma IgG and IgA at 2 years for the 3 strains of virus included in the vaccine, the IgG AI and IgA AI for all 3 strains at 2 years. Bifidobacteria abundance measures were as follows: (1) 
